Drug Trial Radar · NCT04921384
Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine
Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
981
Actual
Start
May 29, 2021
Primary completion
Oct 1, 2024
Study completion Feb 17, 2025
Sponsor
- Lead sponsor
- H. Lundbeck A/SIndustry
- Sponsor type
- Industry
- First posted
- Jun 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the efficacy of eptinezumab to prevent migraine in participants with chronic migraine.
Conditions
- Migraine
Interventions
PlaceboDrug
0.9% normal saline, intravenously
EptinezumabDrug
Solution for infusion, intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the number of monthly migraine days (MMDs) (Weeks 1-12)Time frame: Weeks 1-12
Locations
87 sites in 8 countries. Site status is shown where the registry gives one.
Beijing Chaoyang Hospital Capital Medical University
Beijing, China
Xuanwu Hospital Capital Medical University
Beijing, China
The First Affiliated Hospital With Nanjing Medical University(Jiangsu Province Hospital)
Beijing, China
The First Hospital of Jilin University
Changchun, China
The Second Norman Bethune Hospital of Jilin University - Ziqiang Campus
Changchun, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, China
Jiangxi Pingxiang People's Hospital
Pingxiang, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
The First Medical Center of The Chinese PLA General Hospital (301 Hospital)
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Guangzhou Medical University - Yanjiang Campus
Guangzhou, Guangdong, China
People's Hospital of Zhengzhou
Zhengzhou, Henan, China
Renmin Hospital of Wuhan University - Main Campus
Wuhan, Hubei, China
Malkhaz Katsiashvili Multiprofile Emergency Medicine Center -3 Nakalakevis Kucha
Tbilisi, Georgia
Ltd Israel-Georgia Medical Research Clinic Helsicore
Tbilisi, Georgia
Pineo Medical Ecosystem
Tbilisi, Georgia
Aversi Clinic LTD
Tbilisi, Georgia
MediClubGeorgia Ltd
Tbilisi, Georgia
Multiprofile Clinic Consilium Medulla
Tbilisi, Georgia
S. Khechinashvili University Clinic, Ltd.
Tbilisi, Georgia
DOI Clinic Internal Medicine
Hirosima Naka-ku, Japan
Atsuchi Neurosurgery Hospital
Kagoshima, Japan
Ikeda Neurosurgical Clinic
Kasuga, Japan
Jinnouchi Neurosurgery Clinic
Kasuga-shi, Japan
Shin Matsudakai Atago Hospital
Kochi, Japan
Tatsuoka Neurology Clinic
Kyoto Shimojo-ku, Japan
Dokkyo Medical University Hospital
Mibu-Machi, Japan
Mito Kyodo General Hospital
Mito, Japan
Tominaga Hospital
Naniwa-ku, Japan
Tokyo headache clinic
Shibuya-ku, Japan
Japanese Red Cross Shizuoka Hospital
Shizuoka, Japan
Eiju General Hospital
Taitō City, Japan
Kitasato University Kitasato Institute Hospital
Tokyo, Japan
Toyota Memorial Hospital
Toyota-shi, Japan
Tokyo Dental College Ichikawa General Hospital
Ichikawa-Shi, Chiba, Japan
Nakamura Memorial Hospital
Sapporo-Shi Chuo-Ku, Hokkaidô, Japan
Iwate Medical University Uchimaru Medical Center
Morioka, Iwate, Japan
Sendai Headache and Cranial Nerves Clinic
Sendai-Shi Taihaku-Ku, Miyagi, Japan
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.